PanGIA Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

PanGIA Biotech is pioneering an AI-driven, multi-fluid diagnostic platform centered on a non-invasive 'True Liquid Biopsy' using urine. The company's PanGIA Analysis System (PAS) applies machine learning to colorimetric biomolecular profiles to detect early-stage cancers with the goal of improving accuracy, accessibility, and patient comfort over traditional methods like blood tests or tissue biopsies. While its lead PanGIA Prostate assay is in use globally for diagnostic research, the company is navigating the path toward FDA approval and commercial scale-up to address the significant global need for better early cancer detection.

Oncology

Technology Platform

The PanGIA Analysis System (PAS): An AI-powered diagnostic platform that uses colorimetric biomolecular profiling of urine samples to detect disease signatures. Machine learning algorithms analyze the complex profile to identify patterns indicative of specific cancers.

Opportunities

The massive and growing global burden of cancer creates a urgent need for better early detection tools.

PanGIA's non-invasive, urine-based platform could enable broader screening adoption, especially in underserved populations or for cancers lacking good screening options.

Success with its prostate cancer assay could pave the way for a multi-cancer detection platform in a high-value diagnostics market.

Risk Factors

The company faces significant technical risk in validating its AI/ML platform in large-scale clinical trials and regulatory risk in securing FDA approval.

It operates in the highly competitive multi-cancer early detection space against well-funded rivals with blood-based tests.

Commercial success depends on achieving insurance reimbursement and convincing clinicians to adopt a new paradigm.

Competitive Landscape

PanGIA competes in the crowded liquid biopsy and multi-cancer early detection (MCED) market. Key competitors include GRAIL (Galleri test, blood-based), Exact Sciences, and Freenome. PanGIA's primary differentiation is its use of urine as a sample matrix and its colorimetric/AI profiling approach, positioning it as a potentially more accessible and patient-friendly alternative.

More companies in Diagnostics & Precision Medicine →More companies in United States →